Square Pharmaceuticals PLCDSEBD: SQURPHARMA

SQURPHARMA: Net profit rose 13% year-over-year, with EPS at Tk. 14.32 and strong asset growth

· Issued by Square Pharmaceuticals PLC

Consolidated revenue and net profit grew 6% and 13% year-over-year, with EPS up to Tk. 14.32. Cash flow per share declined due to absence of prior year one-offs, while NAV per share rose to Tk. 145.52.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Square Pharmaceuticals PLC on 6ix

Earlier from Square Pharmaceuticals

Later from Square Pharmaceuticals

All Square Pharmaceuticals news releases